Anagrelide is indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.
FDA,2021.10
Anagrelide, as a platelet-reducing medication, plays an important role in the tr···【more】
Release date:2026-03-27Recommended:187
Anagrelide is used to reduce the platelet count in patients with myeloproliferat···【more】
Release date:2026-01-30Recommended:172
Thrombocythemia【more】
Release date:2026-01-05Recommended:142
LuciusVersionofAnagrelide:DosageandAdministration,Indications,PrecautionsIndicat···【more】
Release date:2025-12-02Recommended:209
Anagrelide is a drug used to treat thrombocythemia, primarily for abnormal eleva···【more】
Release date:2024-12-12Recommended:352